Last updated: February 15, 2026
What Is NDC 00832-1113?
NDC 00832-1113 refers to Imatinib Mesylate tablets, a targeted cancer therapy primarily used to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Imatinib was first introduced by Novartis and remains one of the most prescribed TKIs (Tyrosine Kinase Inhibitors).
Current Market Landscape
Market Size and Growth
- Global Oncology Drug Market (2023): Estimated at $165 billion, with targeted therapies accounting for approximately 40%. CML drugs, including Imatinib, represent a critical segment.
- CML Market (2023): Estimated at $4.2 billion, with Imatinib holding the largest share historically, though declining with the introduction of second- and third-generation TKIs.
- Key Players: Novartis (original manufacturer), Gleevec (brand), generics manufacturers (Indian and Chinese firms).
Patent and Competition
- Patent Expiry: The primary patent for Gleevec (originator brand) expired in the U.S. around 2016, leading to increased generic competition.
- Generics: Multiple biosimilars and generics now available, notably from Zydus Cadila, Dr. Reddy's, and Teva.
- Market Share: Originator’s Gleevec/Glivec holds around 60% of sales in 2020, with generics capturing the remaining 40%.
Price Trends and Projections
Current Pricing
- Brand Name Gleevec (Novartis): Wholesale acquisition cost (WAC) approximately $9,755 per month per patient for 400 mg tablets (as of 2023).
- Generic Imatinib: Prices range from $1,200 to $3,000 per month, depending on manufacturer, dosages, and location.
- Impact of Biosimilars: Introduced biosimilars have reduced prices by approximately 60%, with some markets experiencing even greater discounts.
Factors Influencing Price Trends
- Patent Litigation and Exclusivity: Patent challenges and data exclusivity periods impact generic entry timelines.
- Market Penetration: Larger adoption of biosimilars and generics drives prices downward.
- Regulatory Developments: Approval of biosimilars in the U.S. (e.g., Inflectra, Amjevita) accelerates price reduction.
- Pricing Policies: Some countries enforce price caps, influencing global price levels.
Price Projection (Next 5 Years)
| Year |
Estimated Brand Price (monthly) |
Estimated Generic Price (monthly) |
Notes |
| 2023 |
$9,755 |
$1,200-$3,000 |
Brand remains expensive; generics dominate price cuts. |
| 2024 |
Slight decline for brand, ~$9,500 |
Stabilization around $1,000-$2,800 |
Patent challenges may extend, but biosimilars increase. |
| 2025 |
Further decline for brand, ~$9,200 |
$900-$2,500 |
Increased biosimilar market share. |
| 2026 |
Continued decrease, ~$8,800 |
$800-$2,200 |
More biosimilars gaining approval and market share. |
| 2027 |
Stable with gradual decline, ~$8,500 |
$700-$2,000 |
Market saturation with biosimilars. |
Market Drivers and Barriers
Drivers
- Increased adoption of biosimilars reduces overall treatment costs.
- Growing prevalence of CML and GIST globally.
- Expanded approval for biosimilars in major markets like the U.S., European Union, and Japan.
Barriers
- Slow biosimilar market penetration in some regions due to regulatory and prescriber resistance.
- Market dominance of existing generics and brand-name drugs.
- Intellectual property and patent litigations delaying generics.
Investment and R&D Implications
- Innovative Therapies: Next-generation TKIs like Asciminib show promise but face high R&D costs and long regulatory timelines.
- Market Supply Dynamics: Manufacturers are expanding biosimilar portfolios, further pressuring prices.
- Regulatory Environment: USFDA, EMA, and other agencies increasingly support biosimilar approvals, accelerating price declines.
Regulatory and Policy Outlook
- U.S. FDA: Continues to approve biosimilars, with 24 approved as of 2023.
- European Union: Active biosimilar approval process, with 18 biosimilars approved for oncology drugs.
- National Health Policies: Many countries implement cost containment measures affecting pricing and availability.
Key Takeaways
- Imatinib (NDC 00832-1113) remains a cornerstone in CML and GIST treatment but faces significant generic competition.
- Prices for branded Imatinib continue to decline, primarily driven by biosimilar proliferation.
- By 2027, expected price levels will be substantially lower than current rates, with discounts exceeding 60%.
- The market is consolidating as biosimilars and generics expand access, fostering affordability but challenging profit margins for originator firms.
- Ongoing R&D efforts focus on next-generation therapies, potentially impacting the long-term market landscape.
FAQs
1. How does the arrival of biosimilars affect the Imatinib market?
Biosimilars lower overall drug prices, increase competition, and can lead to market expansion due to improved affordability.
2. What factors influence the timeline for generic entry?
Patent expiration dates, legal challenges, regulatory approval processes, and market incentives impact generic timing and availability.
3. Are there emerging drugs that threaten Imatinib's market dominance?
Yes. Next-generation TKIs like Asciminib, Bosutinib, and Ponatinib expand treatment options, potentially replacing Imatinib in some indications.
4. How do pricing policies vary internationally?
Countries with national health systems often implement price caps or reimbursement policies that lower costs, impacting market prices differently across regions.
5. What are the implications for investors regarding Imatinib?
Investors should monitor patent expirations, biosimilar approvals, and new drug developments, as these factors significantly influence the drug's market value.
References
[1] EvaluatePharma. "Global Oncology Market 2023."
[2] IQVIA. "U.S. Prescription Drug Market Data, 2023."
[3] FDA. "Approved Biosimilars," 2023.
[4] Novartis. "Gleevec/Imatinib Product Data," 2023.
[5] Statista. "Pricing Trends for Oncology Drugs," 2023.
